Clinical trial · Interventional
PHA-739358 for the Treatment of Multiple Myeloma
An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression
NCT00872300CI-TRIAL-00014708terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low recruitment rate
Summary
Brief summary (as posted)
The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PHA-739358 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: PHA-739358
Primary outcomes (1)
- measure
- Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma.
- timeFrame
- At end of each cycle
Secondary outcomes (1)
- measure
- Overall safety profile
- timeFrame
- All cycles
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * active multiple myeloma progressing after at least 2 prior lines of treatment * measurable disease * t(4;14) translocation * life expectancy of at least 3 months Exclusion Criteria: * uncontrolled hypertension * myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months. * pregnancy or breast feeding * active infections, including HIV
References
Publications (0)
Data not yet available
No reference posted for this study.